Del Giorno Rosaria, Berwert Lorenzo, Pianca Silvio, Bianchi Giorgia, Giannini Olivier, Gabutti Luca
Department of Internal Medicine, Nephrology and Dialysis Unit, Regional Hospital of Bellinzona and Valli, Ente Ospedaliero Cantonale, Bellinzona.
Nephrology Unit, Civico Hospital, Ente Ospedaliero Cantonale, Lugano.
Ther Clin Risk Manag. 2017 Oct 16;13:1415-1422. doi: 10.2147/TCRM.S143708. eCollection 2017.
Thrombocytopenia is a potential complication of hemodialysis (HD), and its occurrence has been described even with highly biocompatible polysulfone (PSf) membranes. Dialysis units routinely monitor platelet (PLT) count at the beginning of HD sessions. However, considering that the long-term effects on PLT count could easily be missed, the prevalence of HD-related thrombocytopenia could be underestimated. In the present study, we aimed to investigate the following: 1) the long-term impact of HD treatment on PLT count, comparing two families of dialysis membranes made up of similar PSfs; 2) whether the switch between the dialysis membranes studied significantly affects PLT count; and 3) the prevalence and the risk of HD-induced thrombocytopenia according to the dialysis membranes used.
A cross-sectional retrospective study was performed comprising 157 adult chronic HD patients. The HD membranes under investigation were of the series FX, Helixone Fresenius (Filters A), and Polyflux Gambro (Filters B). Patients were treated in 4 dialysis units in Southern Switzerland. Data were collected from a centralized computing platform.
PLT count significantly differs between Filters A and B with, respectively, 188 (153-243) ×10E9/L versus 214 (179-255) ×10E9/L (=0.036). The prevalence of thrombocytopenia was higher for Filter A compared with Filter B (28.4% versus 12.8%; <0.001). The switch from Filter A to Filter B significantly affected PLT count: from 189 (146-217) ×10E9/L to 217 (163-253) ×10E9/L (<0.001; analysis on 26 patients). A linear random-intercept model confirmed the results (β coefficient =35.214; SE =5.956; <0.001). In a mixed-effects logistic regression model, the risk of thrombocytopenia for Filter B was 0.157 (CI =0.056-0.442).
Our data suggest that among the PSf membranes studied, the FX membrane induced a lasting decrease in PLT count and caused significantly more thrombocytopenia. Prospective studies are warranted to verify our findings.
血小板减少是血液透析(HD)的一种潜在并发症,即使使用具有高度生物相容性的聚砜(PSf)膜也会出现这种情况。透析单位通常在HD治疗开始时监测血小板(PLT)计数。然而,考虑到对PLT计数的长期影响很容易被忽视,与HD相关的血小板减少症的患病率可能被低估。在本研究中,我们旨在调查以下内容:1)HD治疗对PLT计数的长期影响,比较由相似PSf制成的两类透析膜;2)所研究的透析膜之间的切换是否会显著影响PLT计数;3)根据所使用的透析膜,HD诱导的血小板减少症的患病率和风险。
进行了一项横断面回顾性研究,纳入157例成年慢性HD患者。所研究的HD膜为FX系列、费森尤斯Helixone(过滤器A)和金宝Polyflux(过滤器B)。患者在瑞士南部的4个透析单位接受治疗。数据从一个集中计算平台收集。
过滤器A和过滤器B的PLT计数有显著差异,分别为188(153 - 243)×10⁹/L和214(179 - 255)×10⁹/L(P = 0.036)。与过滤器B相比,过滤器A的血小板减少症患病率更高(28.4%对12.8%;P < 0.001)。从过滤器A切换到过滤器B显著影响PLT计数:从189(146 - 217)×10⁹/L变为217(163 - 253)×10⁹/L(P < 0.001;对26例患者的分析)。线性随机截距模型证实了结果(β系数 = 35.214;标准误 = 5.956;P < 0.001)。在混合效应逻辑回归模型中,过滤器B发生血小板减少症的风险为0.157(置信区间 = 0.056 - 0.442)。
我们的数据表明,在所研究的PSf膜中,FX膜导致PLT计数持续下降,并引起显著更多的血小板减少症。有必要进行前瞻性研究以验证我们的发现。